Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

Haematologica

Volumn 90, Issue 10, 2005, Pages 1346-1356

  Ribera, Josep María ^a   Oriol, Albert ^a   Bethencourt, Concepción ^b   Parody, Ricardo ^c   Hernández Rivas, Jesús María ^d   Moreno, María José ^e   Del Potro, Eloy ^f   Tormo, Mar ^g   Rivas, Concepción ^h   Besalduch, Joan ⁱ   Sanz, Miguel Ángel ^j   Ortega, Juan José ^k  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

Acute lymphoblastic leukemia; Adult; Allogeneic; Autologous; Chemotherapy; High risk; Stem cell transplantation

Indexed keywords

ANTIINFECTIVE AGENT; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG RESPONSE; FAMILY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; PATIENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 27144543159     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, et al. A randomised controlled trial of Elgrastim during remission and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92:1556-64.
2. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-61.
3. Ribera JM, Onega JJ, Oriol A, Fontanillas M, Hernandez-Rivas JM, Brunet S, et al. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomised trial (PETHEMA ALL-89). Haematologica 1998;83:222-30.
4. Göckbuget N, Arnold R, Buechner Th. Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1,200 patients in the GMALL study 05/93. Blood 2001;98: 802a.
5. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863-71.
6. Durrant JJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of UK Medical Research Council randomised trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 1997;99:84-92.
7. Rowe JM, Buck G, Burnett AK. Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2003;102:224a.
8. Hoelzer D, Göckbuget N. New approaches in acute lymphoblastic leukemia in adults. Were do we go? Semin Oncol. 2000;27:540-59.
9. Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 2003;10:284-9.
10. Zhang MJ, Hoelzer D, Horowitz MM, Gale RP, Messerer D, Klein JP, et al. Long-term follow-up of adults with acute lymphoblastic leukaemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med 1995;123:428-31.
11. Horowitz MM, Messerer D, Hoelzer D, Gale RP, Neiss A, Atkinson K, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991;115:13-8.
12. Oh H, Gale RP, Zhang MJ, Passweg JR, Ino T, Murakami H, et al. Chemotherapy versus HLA-identical sibling transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 1998;22:253-7.
13. Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma for patients ≤ 50 years old in First complete remission: results of the EORTC ALL-3 trial. Haematologica 2004;89:809-17.
14. Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004;33:397-404.
15. Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994;12: 2580-7.
16. Thiebault A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. Follow-up reports of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000;14:1353-66.
17. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment of adults with acute lymphoblastic leukemia: analysis of LALA-94 trial. J Clin Oncol 2004;22:4075-86.
18. Rowe JM, Richards SM, Burnett AK. Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome- negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2001;98:481a.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of acute leukaemias. French-American- British (FAB) Co-operative Group. Br J Haematol 1976; 33:451-8.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. The morphologic classification of acute lymphoblastic leukaemia. Concordance among observers and clinical correlations. Br J Haematol. 1981;47:553-61.
21. Mitelman F, ed. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger 1995.
22. Kaplan GL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457-81.
23. Peto R, Pike MC. Conservatism of the approximation (O-E)2/E in the log-rank test for survival data or tumour incidence data. Biometrics 1973;29:579-84.
24. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Statistics for Biology and Health. New York, Springer-Verlag, 1997.
25. Cox DR. Regression models and life tables. J Roy Stat Soc Series B 1972;34: 187-220.
26. Simon R, Lee YJ. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep. 1982;66:37-42.
27. Ribera JM, Ortega JJ, Oriol A, Granada I, Hernandez-Rivas JM, Parody R, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002;87:154-66.
28. Urbano-Ispizua A, Scmitz N, De Witte T, Frassoni F, Rosti G, Schrezenmeier H, et al. Allogeneic and autologous transplantation for hematological diseases, solid tumors and immune disorders: definitions and current practices in Europe. Bone Marrow Transplant 2002;29:639-46.
29. Fière D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vemant JP, et al. Adult acute lymphoblastic leukaemia: a multicenter randomized trial testing bone marrow transplantation as post-remission therapy. J Clin Oncol 1993;11:1990-2001.
30. Attal M, Biaise D, Marit G, Payen C, Michallet M, Vemant JP, et al. Consolidation treatment of adult acute lymphoblastic leukaemia: a randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86:1619-28.
31. Deane M, Koch M, Foroni L, Galactowicz G, Hoffbrand AV, Lawler M, et al. FLAG-idarubicin and allogeneic stem-cell transplantation for Ph-positive ALL beyond first remission. Bone Marrow Transplant. 1998;22:1137-43.
32. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997;90:1410-4.
33. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Biaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357-66.
34. Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B, et al. Unrelated bone marrow transplantation for adults with poor-risk acute lymphocytic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572-7.
35. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, et al. Outcome of allogeneic hematopioetic stem cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004; 22:2816-25.
36. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukaemia, Blood 2004;104:3507-12.
37. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407.
38. Ringden O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning regimen for autograft or allograft bone marrow transplantation in patients with acute leukemia: Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996;93:637-45.
39. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003;32:543-8.
40. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-38.
41. Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukaemia. J Clin Oncol 2002;20:1094-104.
42. Vidriales MB, Ferez JJ, Lopez-Berges MC, Gutierrez N, Ciudad J, Lucio P, et al. Minimal residual disease (MRD) in adolescent (>14 years) and adult acute lymphoblastic leukemias (ALL): early immunophenotypical evaluation has high clinical value. Blood 2003;101:4695-700.
43. Göckbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, et al. Treatment of adult ALL according to the protocols of the German Multicenter Study for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000;14:1307-25.
44. Abdallah A, Egerer G Goldschmidt H, Wannenmacher M, Korbling M, Ho AD. Continuous complete remission in adult patients with acute lymphocytic leukemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol 2001;112: 1012-5.
45. Weisdorf DJ, Billett AL, Hanan P, Ritz J, Sallan SE, Steinbuch M, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997;90: 2962-8.
46. Gorin NC. Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells 2002;20:3-10.
47. Powles R Sirohi B, Treleaven J, Kulkami S, Tait D, Singhai S, et al. The role of posttrasplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002;100: 1641-7.
48. Dhedin N, Thomas X, Huguet F. No superiority of autologous stem cell transplantation over chemotherapy alone in adult Ph-negative ALL in first complete remission: A long-term follow-up report combining results of LALA-85, 87 and 94 trials. Blood 2002;100:217a[Abstract].
49. Lee S, Kim DW, Kim YJ, Park YH, Min CK, Lee JW, et al. Influence of karyotype on outcome of allogeneic stem cell transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first and second remission. Br J Haematol 2002;117:109-18.
50. Gorin NC, Labopin M, Folge E, Cordonnier C, Jouet JP, Michallet M, et al. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 2003;17:1596-9.
51. Doney K, Hagglund H, Leisenring W, Chauncey T, Appelbaum FR, Storb R. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2003;9:472-81.
52. Avivi I, Goldstone AH. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 2003;31:623-32.
53. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res 1998;22:973-81.
54. Sweetenham JW, Santini G, Quian W, Guelfi M, Schmitz N, Simnett S, et al. High-dose therapy and autologous stem cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomised trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001;19:2927-36.
55. Goldstone AH, Lazarus HJ, Richards SM, Litzow MR, Chopra R, Burnett AK, et al. The outcome of 551 1st CR transplants in adult ALL from the UKALL XII/ECOG2993 study. Blood 2004;104:178a [abstract].
56. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Acute Leukemia Group B experience. Blood 1999;93:3983-93.
57. Groupe Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative Study of The Groupe Français de Cytogenetique Hematologique. Blood 1996; 87:3135-42.
58. Sebban S, Browman GP, Lepage E, Fière D. Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukaemia: a prospective analysis of 437 cases and its application for designing induction chemotherapy trials. Leuk Res 1995;19:861-8.
59. Hoelzer D, Baur KH, Giagounidis A. Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, mature B-ALL and other high-grade B-NHL. Blood 2003;102:70a[Abstract].
60. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, Yamada T, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with haematological malignancies. Blood 2004; 104:3813-20.
61. Bradfield SM, Radich JP, Loken MR. Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection. Leukemia 2004;18:1156-8.
62. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002;16: 2423-8.
63. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F, et al. Allogeneic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003; 88:555-60.
64. Collins RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000;26:511-6.